Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
AMRX · Nasdaq · United States · Pharmaceutical Preparations
In shortAmneal Pharmaceuticals, Inc. is profitable.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 13.1% | 60/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 2.4% | 30/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 14.5% | 97/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.17× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 5.07× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.06 | 25/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 8.9% | 56/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 3.75× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 4.7% | 94/100 |
| Operating margin volatility | 6.5% | 50/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 10.9% | 77/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 2,094 | 2,212 | 2,394 | 2,794 | 3,019 |
| Cost of revenue | 1,325 | 1,428 | 1,573 | 1,774 | 1,905 |
| Gross profit | 769 | 785 | 821 | 1,020 | 1,113 |
| Research & development | 202 | 196 | 164 | 191 | 186 |
| Selling, general & admin | 366 | 400 | 430 | 476 | 527 |
| Operating income | 153 | (95) | 204 | 249 | 394 |
| Pre-tax income | 31 | (248) | (40) | (55) | 139 |
| Income tax | 11 | 6.7 | 8.5 | 19 | 11 |
| Net income | 13 | (271) | (84) | (117) | 72 |
| Diluted EPS | $0.07 | −$0.86 | −$0.48 | −$0.38 | $0.22 |
| Diluted shares (millions) | 152 | 151 | 176 | 309 | 325 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
2.06 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026